Skip to main content

Table 3 SRS Response rate at follow-up MRI

From: Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment

Treatment

Scan interval, d (range)

CR

PR

Stable

PD

SRS + pembro

(n = 23)

57 (39-118)

8 (35%)

8 (35%)

6 (26%)

1 (4%)

SRS + ipi

(n = 31)

53 (41-95)

4 (13%)

6 (19%)

19 (61%)

2 (6%)

SRS

(n = 27)

51 (28-130)

1 (4%)

5 (19%)

18 (67%)

3 (11%)

  1. Response assessment adapted from RANO proposal (Lin et al. 2015)
  2. CR = complete response (disappearance of target lesion)
  3. PR = partial response (lesion visible, ≥ 30% decrease in max diameter)
  4. Stable = stable response (lesion visible, < 30% decrease OR <20% increase in max diameter)
  5. PD = progressive disease (lesion visible, ≥ 20% increase in max diameter)